Literature DB >> 17593353

Pharmacological evidence for altered src kinase regulation of I (Ca,L) in patients with chronic atrial fibrillation.

Maura Greiser1, Christian R Halaszovich, Dirk Frechen, Peter Boknik, Ursula Ravens, Dobromir Dobrev, Andreas Lückhoff, Ulrich Schotten.   

Abstract

A reduction in L-type Ca(2+) current (I (Ca,L)) contributes to electrical remodeling in chronic atrial fibrillation (AF). Whether the decrease in I (Ca,L) is solely due to a reduction in channel proteins remains controversial. Protein tyrosine kinases (PTK) have been described as potent modulators of I (Ca,L) in cardiomyocytes. We studied alpha(1C) L-type Ca(2+) channel subunit expression and the regulation of I (Ca,L) by PTK in chronic AF using PTK inhibitors: genistein, a nonselective inhibitor of PTK, and 4-amino-5-(4-methylphenyl)-7-(t-butyl)pyrazolo-3,4-d-pyrimidine (PP1), a selective inhibitor of src kinases. Furthermore, type-1 and type-2A protein phosphatase activity was measured with phosphorylase as substrate in whole-cell lysates derived from atrial tissue of AF patients. Right atrial appendages were obtained from patients undergoing open-heart surgery. Protein levels of alpha(1C) L-type Ca(2+) channel subunit were determined using Western blot analysis and normalized to the protein amounts of calsequestrin as internal control. The protein concentrations of alpha(1C) did not differ between AF and sinus rhythm (SR; alpha(1C)/calsequestrin: 1.0 +/- 0.1 and 1.2 +/- 0.2, respectively, n = 8 patients). In cardiomyocytes from patients in SR (n = 20 patients), genistein and PP1 both evoked similar increases in I (Ca,L) from 3.0 +/- 0.3 to 6.1 +/- 0.8 pA/pF and from 2.8 +/- 0.4 to 6.1 +/- 0.6 pA/pF, respectively. In cells from AF patients (n = 10 patients), basal I (Ca,L) was significantly lower. In this case, genistein lead to the same relative increase in I (Ca,L) as in SR cells (from 1.46 +/- 0.30 to 3.2 +/- 1.0 pA/pF), whereas no increase was elicited by PP1 suggesting impaired regulation of I (Ca,L) by src kinases in AF. Total and type 1 and type 2A-related phosphatase activities were higher in tissue from patients with chronic AF compared to SR (4.8 +/- 0.4, 2.1 +/- 0.2, and 2.7 +/- 0.4 nmol/mg/min and 3.6 +/- 0.4, 1.3 +/- 0.2, and 2.4 +/- 0.3 nmol/mg/min, respectively, n = 7 patients per group). Downregulation of I (Ca,L) in AF is not due to a reduction in L-type Ca(2+) channel protein expression. Indirect evidence for an impaired src kinase regulation of I (Ca,L) together with an increased phosphatase activity suggests that a complex alteration in the kinase/phosphatase balance leads to I (Ca,L) dysregulation in chronic AF.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17593353     DOI: 10.1007/s00210-007-0174-6

Source DB:  PubMed          Journal:  Naunyn Schmiedebergs Arch Pharmacol        ISSN: 0028-1298            Impact factor:   3.195


  47 in total

1.  C-terminal fragments of the alpha 1C (CaV1.2) subunit associate with and regulate L-type calcium channels containing C-terminal-truncated alpha 1C subunits.

Authors:  T Gao; A E Cuadra; H Ma; M Bunemann; B L Gerhardstein; T Cheng; R T Eick; M M Hosey
Journal:  J Biol Chem       Date:  2001-03-26       Impact factor: 5.157

2.  Angiotensin II increases L-type Ca2+ current in gramicidin D-perforated adult rabbit ventricular myocytes: comparison with conventional patch-clamp method.

Authors:  Osamu Ichiyanagi; Kuniaki Ishii; Masao Endoh
Journal:  Pflugers Arch       Date:  2002-03-09       Impact factor: 3.657

3.  L-type Ca2+ channels in atrial fibrillation: wallflowers or a vanishing act.

Authors:  Timothy J Kamp; Jason D Foell
Journal:  J Mol Cell Cardiol       Date:  2003-05       Impact factor: 5.000

4.  Differential regulation of voltage-activated potassium currents in cultured human atrial myocytes.

Authors:  S N Hatem; A Bénardeau; C Rücker-Martin; J L Samuel; E Coraboeuf; J J Mercadier
Journal:  Am J Physiol       Date:  1996-10

5.  Ion channel remodeling is related to intraoperative atrial effective refractory periods in patients with paroxysmal and persistent atrial fibrillation.

Authors:  B J Brundel; I C Van Gelder ; R H Henning; R G Tieleman; A E Tuinenburg; M Wietses; J G Grandjean; W H Van Gilst ; H J Crijns
Journal:  Circulation       Date:  2001-02-06       Impact factor: 29.690

6.  Inhibition of Ca2+ current in neonatal and adult rat ventricular myocytes by the tyrosine kinase inhibitor, genistein.

Authors:  Y Katsube; H Yokoshiki; L Nguyen; M Yamamoto; N Sperelakis
Journal:  Eur J Pharmacol       Date:  1998-03-26       Impact factor: 4.432

7.  L-type Ca2+ current in guinea pig ventricular myocytes treated with modulators of tyrosine phosphorylation.

Authors:  T Ogura; L M Shuba; T F McDonald
Journal:  Am J Physiol       Date:  1999-05

Review 8.  Molecular aspects of adrenergic modulation of cardiac L-type Ca2+ channels.

Authors:  Marcel A G van der Heyden; Tessa J M Wijnhoven; Tobias Opthof
Journal:  Cardiovasc Res       Date:  2005-01-01       Impact factor: 10.787

9.  Genistein elicits biphasic effects on L-type Ca2+ current in feline atrial myocytes.

Authors:  Y G Wang; S L Lipsius
Journal:  Am J Physiol       Date:  1998-07

10.  Chronic rapid atrial pacing. Structural, functional, and electrophysiological characteristics of a new model of sustained atrial fibrillation.

Authors:  C A Morillo; G J Klein; D L Jones; C M Guiraudon
Journal:  Circulation       Date:  1995-03-01       Impact factor: 29.690

View more
  26 in total

1.  Remodelling of human atrial K+ currents but not ion channel expression by chronic β-blockade.

Authors:  Gillian E Marshall; Julie A Russell; James O Tellez; Pardeep S Jhund; Susan Currie; John Dempster; Mark R Boyett; Kathleen A Kane; Andrew C Rankin; Antony J Workman
Journal:  Pflugers Arch       Date:  2011-12-08       Impact factor: 3.657

Review 2.  Ion channel remodeling in gastrointestinal inflammation.

Authors:  H I Akbarali; E G Hawkins; G R Ross; M Kang
Journal:  Neurogastroenterol Motil       Date:  2010-07-05       Impact factor: 3.598

Review 3.  Atrial fibrillation therapy now and in the future: drugs, biologicals, and ablation.

Authors:  Christopher E Woods; Jeffrey Olgin
Journal:  Circ Res       Date:  2014-04-25       Impact factor: 17.367

Review 4.  Serine/Threonine Phosphatases in Atrial Fibrillation.

Authors:  Jordi Heijman; Shokoufeh Ghezelbash; Xander H T Wehrens; Dobromir Dobrev
Journal:  J Mol Cell Cardiol       Date:  2017-01-07       Impact factor: 5.000

5.  Cardiomyocyte Ca2+ overload in atrial tachycardia: is blockade of L-type Ca2+ channels a promising approach to prevent electrical remodeling and arrhythmogenesis?

Authors:  Dobromir Dobrev
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2007-12       Impact factor: 3.000

Review 6.  Regulating the regulator: Insights into the cardiac protein phosphatase 1 interactome.

Authors:  David Y Chiang; Albert J R Heck; Dobromir Dobrev; Xander H T Wehrens
Journal:  J Mol Cell Cardiol       Date:  2016-09-20       Impact factor: 5.000

Review 7.  Cardiac adrenergic control and atrial fibrillation.

Authors:  Antony J Workman
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2009-12-04       Impact factor: 3.000

Review 8.  Atrial Ca2+ signaling in atrial fibrillation as an antiarrhythmic drug target.

Authors:  Dobromir Dobrev
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2009-09-26       Impact factor: 3.000

Review 9.  There goes the neighborhood: pathological alterations in T-tubule morphology and consequences for cardiomyocyte Ca2+ handling.

Authors:  William E Louch; Ole M Sejersted; Fredrik Swift
Journal:  J Biomed Biotechnol       Date:  2010-04-08

10.  Cellular bases for human atrial fibrillation.

Authors:  Antony J Workman; Kathleen A Kane; Andrew C Rankin
Journal:  Heart Rhythm       Date:  2008-01-17       Impact factor: 6.343

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.